Profile data is unavailable for this security.
About the company
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
- Revenue in USD (TTM)2.83bn
- Net income in USD-1.86bn
- Incorporated2021
- Employees7.10k
- LocationQuidelOrtho Corp9975 Summers Ridge RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 552-1100
- Fax+1 (858) 453-4338
- Websitehttps://www.quidelortho.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rxsight Inc | 115.18m | -36.77m | 2.10bn | 374.00 | -- | 7.63 | -- | 18.25 | -1.01 | -1.01 | 3.14 | 6.95 | 0.46 | 2.08 | 5.90 | 307,962.60 | -14.69 | -- | -15.83 | -- | 66.26 | -- | -31.93 | -- | 13.34 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
Irhythm Technologies Inc | 537.09m | -131.59m | 2.19bn | 2.00k | -- | 22.03 | -- | 4.07 | -4.26 | -4.26 | 17.40 | 3.18 | 0.7965 | 11.79 | 7.86 | 268,545.50 | -19.51 | -21.92 | -22.66 | -26.77 | 67.19 | 69.39 | -24.50 | -25.75 | 6.76 | -13.78 | 0.8667 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
Conmed Corp | 1.28bn | 98.59m | 2.32bn | 4.00k | 23.86 | 2.63 | 13.60 | 1.82 | 3.15 | 3.15 | 40.81 | 28.61 | 0.5538 | 1.75 | 5.45 | 318,998.30 | 4.28 | 0.8972 | 4.94 | 1.02 | 55.32 | 54.95 | 7.73 | 1.65 | 1.13 | 4.20 | 0.5228 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
Enovis Corp | 1.91bn | -107.11m | 2.44bn | 6.55k | -- | 0.7291 | 16.87 | 1.27 | -1.96 | -1.65 | 35.01 | 59.90 | 0.3872 | 1.53 | 5.52 | 292,209.20 | -2.16 | -0.3569 | -2.37 | -0.41 | 57.30 | 48.19 | -5.57 | -1.06 | 1.08 | 0.836 | 0.2902 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
Myriad Genetics, Inc. | 802.20m | -155.20m | 2.51bn | 2.70k | -- | 3.39 | -- | 3.13 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Inari Medical Inc | 547.47m | -57.05m | 2.55bn | 1.30k | -- | 5.99 | -- | 4.65 | -0.9838 | -0.9838 | 9.43 | 7.29 | 0.9141 | 1.59 | 7.56 | 421,133.80 | -9.53 | -0.5941 | -11.39 | -0.6696 | 87.15 | 89.06 | -10.42 | -0.6295 | 1.45 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
10X Genomics Inc | 631.73m | -239.78m | 2.73bn | 1.26k | -- | 3.77 | -- | 4.33 | -2.02 | -2.02 | 5.31 | 6.01 | 0.6583 | 2.59 | 7.06 | 501,773.60 | -24.99 | -25.52 | -28.04 | -29.05 | 64.70 | 75.88 | -37.96 | -48.53 | 4.42 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
UFP Technologies Inc | 417.47m | 49.55m | 2.75bn | 3.09k | 55.91 | 8.87 | 44.81 | 6.59 | 6.41 | 6.41 | 54.02 | 40.42 | 1.02 | 4.26 | 6.68 | 134,971.50 | 12.08 | 9.69 | 13.85 | 10.95 | 28.02 | 26.33 | 11.87 | 10.14 | 1.63 | 21.63 | 0.1024 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
LivaNova PLC | 1.21bn | -16.59m | 2.76bn | 2.90k | -- | 2.22 | 91.88 | 2.28 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
Tandem Diabetes Care Inc | 796.00m | -136.49m | 2.92bn | 2.40k | -- | 12.49 | -- | 3.67 | -2.09 | -2.09 | 12.21 | 3.57 | 0.8449 | 2.62 | 8.09 | 331,667.50 | -14.49 | -10.08 | -18.58 | -12.23 | 49.06 | 51.77 | -17.15 | -11.59 | 2.38 | -- | 0.598 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
Quidelortho Corp | 2.83bn | -1.86bn | 3.05bn | 7.10k | -- | 0.9599 | -- | 1.08 | -27.79 | -27.79 | 42.35 | 47.30 | 0.372 | 2.58 | 9.15 | 399,239.40 | -24.40 | 11.34 | -27.51 | 12.91 | 47.89 | 62.71 | -65.60 | 20.93 | 0.7929 | 0.7895 | 0.4469 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
Envista Holdings Corp | 2.53bn | -1.32bn | 3.27bn | 12.80k | -- | 1.10 | -- | 1.29 | -7.70 | -7.70 | 14.64 | 17.32 | 0.4207 | 4.08 | 6.37 | 197,937.50 | -21.98 | 1.94 | -26.29 | 2.34 | 54.89 | 57.65 | -52.25 | 5.29 | 1.90 | 3.92 | 0.3357 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
Axonics Inc | 408.81m | -1.71m | 3.53bn | 797.00 | -- | 5.48 | 325.70 | 8.65 | -0.0291 | -0.0291 | 8.11 | 12.61 | 0.5856 | 1.12 | 7.81 | 512,934.80 | -0.2451 | -12.67 | -0.2618 | -13.76 | 75.89 | 70.04 | -0.4185 | -29.68 | 7.11 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
Evolent Health Inc | 2.35bn | -106.20m | 3.61bn | 4.70k | -- | 3.38 | 235.80 | 1.53 | -0.9367 | -0.9367 | 20.71 | 10.79 | 0.9191 | -- | 6.55 | 500,823.00 | -2.91 | -9.60 | -3.63 | -12.59 | 18.57 | 24.50 | -3.16 | -13.66 | -- | -0.2382 | 0.326 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
Neogen Corp | 924.22m | -9.42m | 3.78bn | 2.92k | -- | 1.20 | 35.26 | 4.09 | -0.0435 | -0.0435 | 4.27 | 14.51 | 0.203 | 2.85 | 5.67 | 316,839.90 | -0.207 | 1.38 | -0.214 | 1.44 | 50.19 | 48.23 | -1.02 | 4.31 | 2.59 | 1.19 | 0.2208 | 0.00 | 12.37 | 17.41 | 58.81 | -- | 50.02 | -- |
Haemonetics Corporation | 1.33bn | 114.89m | 3.83bn | 3.66k | 33.52 | 4.23 | 17.55 | 2.87 | 2.23 | 2.23 | 25.92 | 17.70 | 0.5924 | 1.87 | 7.05 | 364,751.20 | 5.10 | 5.02 | 5.74 | 6.07 | 53.58 | 51.74 | 8.61 | 8.11 | 2.33 | 60.20 | 0.5747 | 0.00 | 12.01 | 6.23 | 1.87 | 16.40 | -11.04 | -- |
Holder | Shares | % Held |
---|---|---|
T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 9.49m | 14.12% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 4.79m | 7.13% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 4.40m | 6.54% |
Rubric Capital Management LPas of 30 Jun 2024 | 3.65m | 5.42% |
ArrowMark Colorado Holdings LLCas of 30 Jun 2024 | 2.05m | 3.05% |
Maverick Capital Ltd.as of 30 Jun 2024 | 1.73m | 2.57% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.63m | 2.43% |
D. E. Shaw & Co. LPas of 30 Jun 2024 | 1.56m | 2.32% |
Madison Avenue Partners LPas of 30 Jun 2024 | 1.50m | 2.23% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.20m | 1.78% |